Pharmacogenetics of bipolar disorder

Mansour, Hader; Alda, Martin; Nimgaonkar, Vishwajit L.

doi:10.1007/s11920-002-0044-3

Cited by 9 publications

(7 citation statements)

References 91 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genetic factors also appear to play a significant role in the outcome of long-term lithium treatment [15,16,17,18]. Lithium appears to play an especially important role during the early fetal…”

Section: Introductionmentioning

confidence: 99%

Collagenous Tissues upon Lithium Treatment: A Quantitative Ultrastructural Study

Tzaphlidou

2004

The Scientific World JOURNAL

View full text Add to dashboard Cite

In this review, the influence of lithium treatment in mouse, rat, and rabbit skin, liver, bone, and aorta, as well as arachnoid and dura mater collagen fibrils, is examined using electron microscopy and image processing. Structural changes (fibril architecture and diameter) are detected at the ultrastructural level in specimens from all lithium-treated tissues. The overall collagen fibril architecture is disturbed as compared with specimens from normal species. The mean diameter values of treated collagen fibrils are significantly smaller than those from controls in all tissues examined. The banding patterns of fibrils are normal in all cases. Measurements by a computerized method of measuring axial periodicity of fibrils indicate no effect of lithium on this parameter. Computer analysis shows no differences in charged amino acid composition between lithium-treated and -untreated samples. Under the present experimental conditions, lithium can induce permanent structural collagen alterations.

show abstract

Section: Introductionmentioning

confidence: 99%

Collagenous Tissues upon Lithium Treatment: A Quantitative Ultrastructural Study

Tzaphlidou

2004

The Scientific World JOURNAL

View full text Add to dashboard Cite

show abstract

“…[11][12][13][14][15] The phosphoinositide pathway has been shown to be directly affected by Li through its inhibition of two key enzymes involved in the regeneration of free inositol in the cell. This was further enforced when Berridge et al originally proposed, more than a decade ago, that Li inhibits the dephosphorylation of inositol (1,4,5) phosphate at therapeutic concentrations, and thus depletes cells of free inositol. 16 Recent in vitro experiments further support this initial observation by demonstrating that a deletion of the gene that codes for prolyl oligopeptidase, which regulates inositol metabolism, induces resistance to treatment with Li and valproic acid in Dictyostelium.…”

Section: Mood-stabilizing Drugs Lithiummentioning

confidence: 99%

“…However, in addition to hopes for individualized, that is, less empirically broad treatments of BD patients and more efficient prevention of the most serious side effects to pharmacological treatment, pharmacogenetics in BD have also been used to help refine the phenotype, or in other words, to reduce phenotypic heterogeneity. [5][6][7] BD is treated at both the prophylactic and episodic level. Prophylactic treatment attempts to prevent the occurrence of either depressive or manic episodes, and until recently, it has been carried out primarily with lithium (Li).…”

Section: Introductionmentioning

confidence: 99%

Pharmacogenetics and bipolar disorder

et al. 2004

View full text Add to dashboard Cite

Bipolar disorder (BD) is a major psychiatric condition that commonly requires prophylactic and episodic treatment. There is important variability in the therapeutic response and side-effect profiles to currently available pharmacological agents. Pharmacogenetics have provided new hopes to develop more efficient treatment strategies tailored to the individual patient's needs. This review assesses nonsystematically studies using pharmacogenetic strategies in BD. Most of these studies have focused on patients selected according to lithium response, and more recently, a growing number of studies have been investigating genetic factors in mixed samples of patients classified according to response to antidepressant treatment. Although previous clinical and family studies support the use of pharmacogenetic strategies both to increase phenotype homogeneity as well as to identify genetic factors that may mediate response to treatment, most molecular studies carried out to date are still preliminary and in need of external validation. A major problem has been comparability between studies, in part, because of differences in the criteria used to define response. More attention should be paid to standardize the criteria for drug response definition.

show abstract

“…The phosphoinositide pathway has been directly affected by lithium through its inhibition of two key enzymes involved in the regeneration of free inositol in the cell. This was further enforced when Berridge et al [16] originally proposed, more than a decade ago, that lithium inhibits the dephosphorylation of inositol [1,4,5] phosphate at therapeutic concentrations, and thus depletes cells of free inositol. Recent in vitro experiments further support this initial observation by demonstrating that a deletion of the gene that codes for prolyl oligopeptidase, which regulates inositol metabolism, induces resistance to treatment with lithium and valproic acid in Dictyostelium [17,18•].…”

Section: Lithiummentioning

confidence: 99%

“…Therefore, the utilization of pharmacogenetics in BD has created hope for a more personalized and less empirically broad treatment of BD and a more efficient prevention of the most serious side effects to prophylactic and episodic treatments. However, in addition to finding a correlation between genetic variation and drug effects, pharmacogenetics in BD has also been used to help refine the phenotype or, in other words, to reduce phenotypic heterogeneity [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Long-term responsiveness to lithium as a pharmacogenetic outcome variable: Treatment and etiologic implications

Mamdani¹,

Groisman²,

Alda³

et al. 2003

Curr Psychiatry Rep

Self Cite

View full text Add to dashboard Cite

The importance of genes in the etiology of bipolar disorder has been substantiated through family, twin, and adoption studies. Bipolar disorder is treated at the prophylactic and episodic levels; lithium is one of the most common forms of prophylactic treatment. Recently, pharmacogenetics has come to play an active role in the elucidation of genetic factors that may play a role in modulating lithium response. This strategy has provided hope for advancements in understanding the genetics of lithium-responsive bipolar disorder. This review encompasses studies that have used populations of lithium responders and non-responders to carry out family, linkage, or association studies, as well as some insight into possible mechanisms by which lithium produces its prophylactic effect. Although data examining the pharmacogenetics of bipolar disorder remain scarce, this is a promising avenue of investigation to help genetically define more homogeneous populations or to search for genetic predictors of drug response.

show abstract

Pharmacogenetics of bipolar disorder

Cited by 9 publications

References 91 publications

Collagenous Tissues upon Lithium Treatment: A Quantitative Ultrastructural Study

Collagenous Tissues upon Lithium Treatment: A Quantitative Ultrastructural Study

Pharmacogenetics and bipolar disorder

Long-term responsiveness to lithium as a pharmacogenetic outcome variable: Treatment and etiologic implications

Contact Info

Product

Resources

About